Anti-Tuberculosis Therapeutics Market Growth, Trends and Forecast by 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Coverage: Anti-Tuberculosis Therapeutics Market covers analysis By Drug Class (Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Aminoglycosides, Others); End User (Hospitals & Clinics, Government Agencies, Non Profit Organizations, Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00008533
  • Category : Life Sciences
  • Status : Upcoming
  • No. of Pages : 150
Buy Now

MARKET INTRODUCTION



Tuberculosis (TB) treatment is completed over a long period, and constant medicine and monitoring is needed during the treatment. This eventually results in complete high treatment costs. Increasing prevalence of pediatric tuberculosis and growing incidence of multi-drug-resistant tuberculosis (MDR TB) and extensively drug-resistant (XDR) TB incidences are more driving the growth of the market.

MARKET DYNAMICS



The anti-tuberculosis therapeutics market is projected to grow in the forecast period owing to growing prevalence of tuberculosis, rising government initiative for tuberculosis awareness, increasing healthcare expenditure and developed diagnostic strategies. Moreover, the upsurge in number of hospitals and clinics for TB is also offering opportunities in market growth during the forecast period.

MARKET SCOPE



The "Global Anti-Tuberculosis Therapeutics Market Analysis to 2031" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of anti-tuberculosis therapeutics market with detailed market segmentation by drug class, end user and geography. The global anti-tuberculosis therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Anti-tuberculosis therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION



The global anti-tuberculosis therapeutics market is segmented on the basis of drug class and end user. Based on drug class, the market is segmented into isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, aminoglycosides, and others. Based on end user, the anti-tuberculosis therapeutics market is segmented into hospitals & clinics, government agencies, non profit organizations, and others.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global anti-tuberculosis therapeutics market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anti-tuberculosis therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting anti-tuberculosis therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anti-tuberculosis therapeutics market in these regions.


MARKET PLAYERS



The report covers key developments in the Anti-tuberculosis therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Anti-tuberculosis therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for Anti-tuberculosis therapeutics market in the global market. Below mentioned is the list of few companies engaged in the Anti-tuberculosis therapeutics market.

The report also includes the profiles of key Anti-tuberculosis therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Macleods Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
- LUPIN
- Novartis AG
- AstraZeneca PLC
- Eli Lilly And Company
- GlaxoSmithKline Plc.
- Sanofi

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Anti-Tuberculosis Therapeutics Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) XX%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Drug Class
  • Isoniazid
  • Rifampin
  • Ethambutol
  • Pyrazinamide
  • Fluoroquinolones
  • Aminoglycosides
By End User
  • Hospitals & Clinics
  • Government Agencies
  • Non Profit Organizations
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Macleods Pharmaceuticals Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • LUPIN
  • Novartis AG
  • AstraZeneca PLC
  • Eli Lilly And Company
  • GlaxoSmithKline Plc.
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    anti-tuberculosis-therapeutics-market-report-deliverables-img1
    anti-tuberculosis-therapeutics-market-report-deliverables-img2
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    The List of Companies

    1. Macleods Pharmaceuticals Ltd.
    2. Otsuka Pharmaceutical Co., Ltd.
    3. Johnson & Johnson Services, Inc.
    4. Pfizer Inc.
    5. LUPIN
    6. Novartis AG
    7. AstraZeneca PLC
    8. Eli Lilly And Company
    9. GlaxoSmithKline Plc.
    10. Sanofi
    anti-tuberculosis-therapeutics-market-cagr